Table 4.

Unadjusted and adjusted cox proportional hazards model for disease progression.

	N	Unadjusted HR (95% CI)	P-value	Fully Adjusted HR (95% CI)	P-value
Treatment
PC group	36 (49.3%)	1.0		1.0
PA group	27 (37.0%)	0.3 (0.2, 0.6)	<0.001	0.4 (0.2, 0.7)	0.005
PAC group	10 (13.7%)	0.5 (0.2, 1.1)	0.071	0.3 (0.1, 0.8)	0.012

Fully adjusted model adjusts for Smoking history; Pathological Type; Brain Metastasis; Bone Metastasis; Adrenal Metastasis; EGFR mutation; PD-L1 TPS.

PC group: PD-1/PD-L1 inhibitors plus Chemotherapy.

PA group: PD-1/PD-L1 inhibitors plus anti-angiogenic agents.

PAC group: PD-1/PD-L1 inhibitors plus anti-angiogenic agents plus Chemotherapy.

HR, Hazard Ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; EGFR, Epidermal Growth Factor Receptor.

PD-L1 TPS, Programmed Cell Death-Ligand 1 Tumor cell Proportion Score.